Completed PHASE1 INTERVENTIONAL 2-arm NCT04829916

A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery

A Phase 1b, Randomised, Double-Blind, Parallel Treatment Group Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of RMC-035 in Subjects Undergoing Non-Emergent On-Pump Coronary Artery Bypass Graft and/or Valve Surgery

Sponsor: Guard Therapeutics AB

Conditions Acute Kidney Injury (AKI)

Interventions Placebo RMC-035

Updated 6 times since 2021 Last updated: Apr 18, 2024 Started: Mar 16, 2021 Primary completion: Jul 15, 2021 Completion: Jul 15, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Acute Kidney Injury (AKI) and is currently completed. Guard Therapeutics AB leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2024 — Jul 2024 [monthly]

Completed PHASE1
Jan 2024 — May 2024 [monthly]

Completed PHASE1
Sep 2021 — Jan 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed

▶ Show 1 earlier version

May 2021 — Sep 2021 [monthly]

Recruiting PHASE1

First recorded

Mar 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guard Therapeutics AB

Data source: Guard Therapeutics AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Münster, Germany